Hold on. Are you not are getting carried away?
The potential number of OA sufferers may be up
10 times the number of people affected by RA.
However the return per patient is likely to be
only one twentieth for iPPS compared to the
return for Humira per patient.
A price of $4000 compared with $84000 has
been bandied around.
Also, one would imagine that distribution will
take a bigger slice of the cake, as PAR would be
at distinct disadvantage to a large Pharma
like Abbie.
Still, if it all comes off, it will be a phenomenal
market.
Chart, page-2474
-
- There are more pages in this discussion • 1,829 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
-0.010(5.00%) |
Mkt cap ! $66.54M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 21.0¢ | 19.0¢ | $203.4K | 1.019M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 387930 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 65468 | 2 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |